- Home
- KPRX vs TTOO Comparison
KPRX vs TTOO Comparison
Compare KPRX & TTOO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- TTOO
- Stock Information
- Founded
- KPRX 1998
- TTOO 2006
- Country
- KPRX United States
- TTOO United States
- Employees
- KPRX N/A
- TTOO N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- TTOO Medical/Dental Instruments
- Sector
- KPRX Health Care
- TTOO Health Care
- Exchange
- KPRX Nasdaq
- TTOO Nasdaq
- Market Cap
- KPRX 10.0M
- TTOO 10.7M
- IPO Year
- KPRX N/A
- TTOO 2014
- Fundamental
- Price
- KPRX $3.91
- TTOO $0.27
- Analyst Decision
- KPRX Strong Buy
- TTOO Hold
- Analyst Count
- KPRX 1
- TTOO 1
- Target Price
- KPRX $10.00
- TTOO $5.00
- AVG Volume (30 Days)
- KPRX 54.6K
- TTOO 877.9K
- Earning Date
- KPRX 11-08-2024
- TTOO 02-13-2025
- Dividend Yield
- KPRX N/A
- TTOO N/A
- EPS Growth
- KPRX N/A
- TTOO N/A
- EPS
- KPRX 1.69
- TTOO N/A
- Revenue
- KPRX $16,020,000.00
- TTOO $7,677,000.00
- Revenue This Year
- KPRX N/A
- TTOO $50.31
- Revenue Next Year
- KPRX N/A
- TTOO $117.92
- P/E Ratio
- KPRX $2.31
- TTOO N/A
- Revenue Growth
- KPRX N/A
- TTOO N/A
- 52 Week Low
- KPRX $3.00
- TTOO $0.25
- 52 Week High
- KPRX $8.98
- TTOO $6.95
- Technical
- Relative Strength Index (RSI)
- KPRX 60.98
- TTOO 25.65
- Support Level
- KPRX $3.10
- TTOO $0.25
- Resistance Level
- KPRX $4.00
- TTOO $0.43
- Average True Range (ATR)
- KPRX 0.25
- TTOO 0.04
- MACD
- KPRX 0.02
- TTOO -0.00
- Stochastic Oscillator
- KPRX 90.00
- TTOO 7.80
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About TTOO T2 Biosystems Inc.
T2 Biosystems Inc is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. It is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. The company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance technology.